| 1 | repeat | 3,395 |
| 2 | clean | 1,006 |
| 3 | first-time | 989 |
| 4 | deliberate | 255 |
| 5 | same-day | 169 |
| 6 | second-look | 169 |
| 7 | bioassay-guided | 130 |
| 8 | target-vessel | 87 |
| 9 | second-stage | 77 |
| 10 | first-stage | 68 |
| 11 | dirty | 57 |
| 12 | target-lesion | 56 |
| 13 | yo-yo | 50 |
| 14 | 12-core | 43 |
| 15 | bioactivity-guided | 40 |
| 16 | non-sterile | 31 |
| 17 | activity-guided | 29 |
| 18 | 308-nm | 28 |
| 19 | nonelective | 27 |
| 20 | bioguided | 24 |
| 21 | free/total | 22 |
| 22 | bio-guided | 17 |
| 23 | nonoptimal | 17 |
| 24 | symptom-driven | 17 |
| 25 | 10-core | 16 |
| 26 | celebrity | 16 |
| 27 | full-night | 16 |
| 28 | loughborough | 14 |
| 29 | no-cost | 14 |
| 30 | mechanochemical | 13 |
| 31 | middle-of-the-night | 13 |
| 32 | semi-urgent | 13 |
| 33 | for-cause | 12 |
| 34 | fixed-interval | 11 |
| 35 | four-quadrant | 11 |
| 36 | pulmonary-vein | 11 |
| 37 | i-125 | 9 |
| 38 | less-frequent | 9 |
| 39 | 'morning | 8 |
| 40 | face-to | 8 |
| 41 | homophobic | 8 |
| 42 | nonanatomic | 8 |
| 43 | assay-guided | 7 |
| 44 | bioactivity-directed | 7 |
| 45 | hivnet | 7 |
| 46 | parasite-free | 7 |
| 47 | colposcopic-directed | 6 |
| 48 | bioassay-directed | 5 |
| 49 | intra-placental | 5 |
| 50 | krf | 5 |
| 51 | pre-adoptive | 5 |
| 52 | ringleader | 5 |
| 53 | riva | 5 |
| 54 | syringe-fed | 5 |
| 55 | transhumeral | 5 |
| 56 | yoyo | 5 |
| 57 | 1-segment | 4 |
| 58 | 4130 | 4 |
| 59 | activity-directed | 4 |
| 60 | clinical-guided | 4 |
| 61 | father-daughter | 4 |
| 62 | hypocitraturic | 4 |
| 63 | rt-pa. | 4 |
| 64 | 'repeat | 3 |
| 65 | 20-core | 3 |
| 66 | 23-day | 3 |
| 67 | bi-hourly | 3 |
| 68 | halogen-based | 3 |
| 69 | late-1st | 3 |
| 70 | mercaptoacetyltriglycine-3 | 3 |
| 71 | moon-shaped | 3 |
| 72 | non-radiolabeled | 3 |
| 73 | terminolateral | 3 |
| 74 | 10-15-20 | 2 |
| 75 | 193-nm | 2 |
| 76 | 256-day | 2 |
| 77 | 6,703 | 2 |
| 78 | 904nm | 2 |
| 79 | bio-assay-guided | 2 |
| 80 | bio-guide | 2 |
| 81 | btk/distal | 2 |
| 82 | catched | 2 |
| 83 | first-instar | 2 |
| 84 | half-increment | 2 |
| 85 | low-transverse | 2 |
| 86 | melphalan-based | 2 |
| 87 | no/late | 2 |
| 88 | non-predatory | 2 |
| 89 | non-reacting | 2 |
| 90 | non-target-vessel | 2 |
| 91 | pharmacology-driven | 2 |
| 92 | pre-termination | 2 |
| 93 | rapid-flow | 2 |
| 94 | reduced-activity | 2 |
| 95 | serine/arginine | 2 |
| 96 | short-scar | 2 |
| 97 | suction-above-the-cuff | 2 |
| 98 | superpulsed | 2 |
| 99 | transmeatal | 2 |
| 100 | trimodular | 2 |
| 101 | 'date | 1 |
| 102 | 'post-partum | 1 |
| 103 | .41±1.99 | 1 |
| 104 | 02º | 1 |
| 105 | 1-based | 1 |
| 106 | 136,638 | 1 |
| 107 | 14,777 | 1 |
| 108 | 15-consecutive-day | 1 |
| 109 | 16,621 | 1 |
| 110 | 2.5w | 1 |
| 111 | 3-based | 1 |
| 112 | 3/7-dependent | 1 |
| 113 | 30-w | 1 |
| 114 | 35,136 | 1 |
| 115 | 49,528 | 1 |
| 116 | 5,866 | 1 |
| 117 | 635-nm | 1 |
| 118 | 7473 | 1 |
| 119 | 93,681 | 1 |
| 120 | ac/ac | 1 |
| 121 | adiponectin-mediated | 1 |
| 122 | adult-style | 1 |
| 123 | agc/asc-h/hsil+ | 1 |
| 124 | alcohol-fuelled | 1 |
| 125 | all-consuming | 1 |
| 126 | aminosilanetrithiol | 1 |
| 127 | angry-neutral | 1 |
| 128 | axillofemoral | 1 |
| 129 | backward-word | 1 |
| 130 | bio-directed | 1 |
| 131 | bioactive-guided | 1 |
| 132 | bioguided-assay | 1 |
| 133 | biological-medical | 1 |
| 134 | bypass-first | 1 |
| 135 | cg-rich | 1 |
| 136 | closed-port | 1 |
| 137 | coronary/carotid | 1 |
| 138 | cup-cage | 1 |
| 139 | cuyahoga | 1 |
| 140 | cystoscopy/bladder | 1 |
| 141 | cytotoxic-guided | 1 |
| 142 | daily-practice | 1 |
| 143 | die-face | 1 |
| 144 | distractor-induced | 1 |
| 145 | drug-injecting | 1 |
| 146 | esthetic-only | 1 |
| 147 | euglenoid | 1 |
| 148 | exercise-echocardiographic | 1 |
| 149 | fgfr3-targeted | 1 |
| 150 | geiger-muller | 1 |
| 151 | genotype-informed | 1 |
| 152 | gettered | 1 |
| 153 | glu-pro | 1 |
| 154 | government-imposed | 1 |
| 155 | groups.general | 1 |
| 156 | half-unit | 1 |
| 157 | high-medical-lethality | 1 |
| 158 | high-vaginal | 1 |
| 159 | hsvtk-tcd34 | 1 |
| 160 | hummus-based | 1 |
| 161 | hypertonicity-resistant | 1 |
| 162 | jehovah’s | 1 |
| 163 | kras/tp53 | 1 |
| 164 | lc-ms-guided | 1 |
| 165 | left-prefrontal | 1 |
| 166 | low-medical-lethality | 1 |
| 167 | mel-80 | 1 |
| 168 | multiple-rod | 1 |
| 169 | non-culprit-artery | 1 |
| 170 | non-ebf | 1 |
| 171 | non-mandatory | 1 |
| 172 | nonrectal | 1 |
| 173 | nrusing | 1 |
| 174 | output.• | 1 |
| 175 | over-daily | 1 |
| 176 | parainflammation-driven | 1 |
| 177 | pediveliger | 1 |
| 178 | plate-cage | 1 |
| 179 | roentgenendovascular | 1 |
| 180 | sarcophagid | 1 |
| 181 | sdc1 | 1 |
| 182 | semicontrolled | 1 |
| 183 | single-ctc | 1 |
| 184 | sole-therapy | 1 |
| 185 | spasmophilic | 1 |
| 186 | spectroscopy-guided | 1 |
| 187 | sucrose-density | 1 |
| 188 | sugammadex/placebo | 1 |
| 189 | superagonistic | 1 |
| 190 | suprapreputial | 1 |
| 191 | symptom-limiting | 1 |
| 192 | symptoms.semirigid | 1 |
| 193 | target\vessel | 1 |
| 194 | terawatt | 1 |
| 195 | ugt1a6*1/*1 | 1 |
| 196 | unihemispheric | 1 |
| 197 | user-uploaded | 1 |
| 198 | vaginal/rectal | 1 |
| 199 | viability-guided | 1 |
| 200 | weight-band | 1 |
| 201 | yomann | 1 |
| 202 | δr-guided | 1 |
| 203 | ∼8000 | 1 |
| 1 | 'date | 1 |
| 2 | 'morning | 8 |
| 3 | 'post-partum | 1 |
| 4 | 'repeat | 3 |
| 5 | .41±1.99 | 1 |
| 6 | 02º | 1 |
| 7 | 1-based | 1 |
| 8 | 1-segment | 4 |
| 9 | 10-15-20 | 2 |
| 10 | 10-core | 16 |
| 11 | 12-core | 43 |
| 12 | 136,638 | 1 |
| 13 | 14,777 | 1 |
| 14 | 15-consecutive-day | 1 |
| 15 | 16,621 | 1 |
| 16 | 193-nm | 2 |
| 17 | 2.5w | 1 |
| 18 | 20-core | 3 |
| 19 | 23-day | 3 |
| 20 | 256-day | 2 |
| 21 | 3-based | 1 |
| 22 | 3/7-dependent | 1 |
| 23 | 30-w | 1 |
| 24 | 308-nm | 28 |
| 25 | 35,136 | 1 |
| 26 | 4130 | 4 |
| 27 | 49,528 | 1 |
| 28 | 5,866 | 1 |
| 29 | 6,703 | 2 |
| 30 | 635-nm | 1 |
| 31 | 7473 | 1 |
| 32 | 904nm | 2 |
| 33 | 93,681 | 1 |
| 34 | ac/ac | 1 |
| 35 | activity-directed | 4 |
| 36 | activity-guided | 29 |
| 37 | adiponectin-mediated | 1 |
| 38 | adult-style | 1 |
| 39 | agc/asc-h/hsil+ | 1 |
| 40 | alcohol-fuelled | 1 |
| 41 | all-consuming | 1 |
| 42 | aminosilanetrithiol | 1 |
| 43 | angry-neutral | 1 |
| 44 | assay-guided | 7 |
| 45 | axillofemoral | 1 |
| 46 | backward-word | 1 |
| 47 | bi-hourly | 3 |
| 48 | bio-assay-guided | 2 |
| 49 | bio-directed | 1 |
| 50 | bio-guide | 2 |
| 51 | bio-guided | 17 |
| 52 | bioactive-guided | 1 |
| 53 | bioactivity-directed | 7 |
| 54 | bioactivity-guided | 40 |
| 55 | bioassay-directed | 5 |
| 56 | bioassay-guided | 130 |
| 57 | bioguided | 24 |
| 58 | bioguided-assay | 1 |
| 59 | biological-medical | 1 |
| 60 | btk/distal | 2 |
| 61 | bypass-first | 1 |
| 62 | catched | 2 |
| 63 | celebrity | 16 |
| 64 | cg-rich | 1 |
| 65 | clean | 1,006 |
| 66 | clinical-guided | 4 |
| 67 | closed-port | 1 |
| 68 | colposcopic-directed | 6 |
| 69 | coronary/carotid | 1 |
| 70 | cup-cage | 1 |
| 71 | cuyahoga | 1 |
| 72 | cystoscopy/bladder | 1 |
| 73 | cytotoxic-guided | 1 |
| 74 | daily-practice | 1 |
| 75 | deliberate | 255 |
| 76 | die-face | 1 |
| 77 | dirty | 57 |
| 78 | distractor-induced | 1 |
| 79 | drug-injecting | 1 |
| 80 | esthetic-only | 1 |
| 81 | euglenoid | 1 |
| 82 | exercise-echocardiographic | 1 |
| 83 | face-to | 8 |
| 84 | father-daughter | 4 |
| 85 | fgfr3-targeted | 1 |
| 86 | first-instar | 2 |
| 87 | first-stage | 68 |
| 88 | first-time | 989 |
| 89 | fixed-interval | 11 |
| 90 | for-cause | 12 |
| 91 | four-quadrant | 11 |
| 92 | free/total | 22 |
| 93 | full-night | 16 |
| 94 | geiger-muller | 1 |
| 95 | genotype-informed | 1 |
| 96 | gettered | 1 |
| 97 | glu-pro | 1 |
| 98 | government-imposed | 1 |
| 99 | groups.general | 1 |
| 100 | half-increment | 2 |
| 101 | half-unit | 1 |
| 102 | halogen-based | 3 |
| 103 | high-medical-lethality | 1 |
| 104 | high-vaginal | 1 |
| 105 | hivnet | 7 |
| 106 | homophobic | 8 |
| 107 | hsvtk-tcd34 | 1 |
| 108 | hummus-based | 1 |
| 109 | hypertonicity-resistant | 1 |
| 110 | hypocitraturic | 4 |
| 111 | i-125 | 9 |
| 112 | intra-placental | 5 |
| 113 | jehovah’s | 1 |
| 114 | kras/tp53 | 1 |
| 115 | krf | 5 |
| 116 | late-1st | 3 |
| 117 | lc-ms-guided | 1 |
| 118 | left-prefrontal | 1 |
| 119 | less-frequent | 9 |
| 120 | loughborough | 14 |
| 121 | low-medical-lethality | 1 |
| 122 | low-transverse | 2 |
| 123 | mechanochemical | 13 |
| 124 | mel-80 | 1 |
| 125 | melphalan-based | 2 |
| 126 | mercaptoacetyltriglycine-3 | 3 |
| 127 | middle-of-the-night | 13 |
| 128 | moon-shaped | 3 |
| 129 | multiple-rod | 1 |
| 130 | no-cost | 14 |
| 131 | no/late | 2 |
| 132 | non-culprit-artery | 1 |
| 133 | non-ebf | 1 |
| 134 | non-mandatory | 1 |
| 135 | non-predatory | 2 |
| 136 | non-radiolabeled | 3 |
| 137 | non-reacting | 2 |
| 138 | non-sterile | 31 |
| 139 | non-target-vessel | 2 |
| 140 | nonanatomic | 8 |
| 141 | nonelective | 27 |
| 142 | nonoptimal | 17 |
| 143 | nonrectal | 1 |
| 144 | nrusing | 1 |
| 145 | output.• | 1 |
| 146 | over-daily | 1 |
| 147 | parainflammation-driven | 1 |
| 148 | parasite-free | 7 |
| 149 | pediveliger | 1 |
| 150 | pharmacology-driven | 2 |
| 151 | plate-cage | 1 |
| 152 | pre-adoptive | 5 |
| 153 | pre-termination | 2 |
| 154 | pulmonary-vein | 11 |
| 155 | rapid-flow | 2 |
| 156 | reduced-activity | 2 |
| 157 | repeat | 3,395 |
| 158 | ringleader | 5 |
| 159 | riva | 5 |
| 160 | roentgenendovascular | 1 |
| 161 | rt-pa. | 4 |
| 162 | same-day | 169 |
| 163 | sarcophagid | 1 |
| 164 | sdc1 | 1 |
| 165 | second-look | 169 |
| 166 | second-stage | 77 |
| 167 | semi-urgent | 13 |
| 168 | semicontrolled | 1 |
| 169 | serine/arginine | 2 |
| 170 | short-scar | 2 |
| 171 | single-ctc | 1 |
| 172 | sole-therapy | 1 |
| 173 | spasmophilic | 1 |
| 174 | spectroscopy-guided | 1 |
| 175 | sucrose-density | 1 |
| 176 | suction-above-the-cuff | 2 |
| 177 | sugammadex/placebo | 1 |
| 178 | superagonistic | 1 |
| 179 | superpulsed | 2 |
| 180 | suprapreputial | 1 |
| 181 | symptom-driven | 17 |
| 182 | symptom-limiting | 1 |
| 183 | symptoms.semirigid | 1 |
| 184 | syringe-fed | 5 |
| 185 | target-lesion | 56 |
| 186 | target-vessel | 87 |
| 187 | target\vessel | 1 |
| 188 | terawatt | 1 |
| 189 | terminolateral | 3 |
| 190 | transhumeral | 5 |
| 191 | transmeatal | 2 |
| 192 | trimodular | 2 |
| 193 | ugt1a6*1/*1 | 1 |
| 194 | unihemispheric | 1 |
| 195 | user-uploaded | 1 |
| 196 | vaginal/rectal | 1 |
| 197 | viability-guided | 1 |
| 198 | weight-band | 1 |
| 199 | yo-yo | 50 |
| 200 | yomann | 1 |
| 201 | yoyo | 5 |
| 202 | δr-guided | 1 |
| 203 | ∼8000 | 1 |
| 1 | agc/asc-h/hsil+ | 1 |
| 2 | rt-pa. | 4 |
| 3 | ∼8000 | 1 |
| 4 | 10-15-20 | 2 |
| 5 | 4130 | 4 |
| 6 | mel-80 | 1 |
| 7 | ugt1a6*1/*1 | 1 |
| 8 | 16,621 | 1 |
| 9 | 93,681 | 1 |
| 10 | sdc1 | 1 |
| 11 | mercaptoacetyltriglycine-3 | 3 |
| 12 | 6,703 | 2 |
| 13 | kras/tp53 | 1 |
| 14 | 7473 | 1 |
| 15 | hsvtk-tcd34 | 1 |
| 16 | i-125 | 9 |
| 17 | 35,136 | 1 |
| 18 | 5,866 | 1 |
| 19 | 14,777 | 1 |
| 20 | 49,528 | 1 |
| 21 | 136,638 | 1 |
| 22 | .41±1.99 | 1 |
| 23 | cuyahoga | 1 |
| 24 | riva | 5 |
| 25 | ac/ac | 1 |
| 26 | homophobic | 8 |
| 27 | exercise-echocardiographic | 1 |
| 28 | spasmophilic | 1 |
| 29 | nonanatomic | 8 |
| 30 | unihemispheric | 1 |
| 31 | hypocitraturic | 4 |
| 32 | superagonistic | 1 |
| 33 | single-ctc | 1 |
| 34 | distractor-induced | 1 |
| 35 | user-uploaded | 1 |
| 36 | cytotoxic-guided | 1 |
| 37 | bioactive-guided | 1 |
| 38 | clinical-guided | 4 |
| 39 | bio-guided | 17 |
| 40 | δr-guided | 1 |
| 41 | lc-ms-guided | 1 |
| 42 | assay-guided | 7 |
| 43 | bio-assay-guided | 2 |
| 44 | bioassay-guided | 130 |
| 45 | spectroscopy-guided | 1 |
| 46 | viability-guided | 1 |
| 47 | activity-guided | 29 |
| 48 | bioactivity-guided | 40 |
| 49 | bioguided | 24 |
| 50 | syringe-fed | 5 |
| 51 | catched | 2 |
| 52 | non-radiolabeled | 3 |
| 53 | alcohol-fuelled | 1 |
| 54 | semicontrolled | 1 |
| 55 | genotype-informed | 1 |
| 56 | moon-shaped | 3 |
| 57 | gettered | 1 |
| 58 | 1-based | 1 |
| 59 | 3-based | 1 |
| 60 | melphalan-based | 2 |
| 61 | halogen-based | 3 |
| 62 | hummus-based | 1 |
| 63 | superpulsed | 2 |
| 64 | government-imposed | 1 |
| 65 | adiponectin-mediated | 1 |
| 66 | colposcopic-directed | 6 |
| 67 | bio-directed | 1 |
| 68 | bioassay-directed | 5 |
| 69 | activity-directed | 4 |
| 70 | bioactivity-directed | 7 |
| 71 | fgfr3-targeted | 1 |
| 72 | sarcophagid | 1 |
| 73 | symptoms.semirigid | 1 |
| 74 | euglenoid | 1 |
| 75 | coronary/carotid | 1 |
| 76 | weight-band | 1 |
| 77 | multiple-rod | 1 |
| 78 | backward-word | 1 |
| 79 | die-face | 1 |
| 80 | daily-practice | 1 |
| 81 | bio-guide | 2 |
| 82 | parasite-free | 7 |
| 83 | plate-cage | 1 |
| 84 | cup-cage | 1 |
| 85 | second-stage | 77 |
| 86 | first-stage | 68 |
| 87 | non-sterile | 31 |
| 88 | adult-style | 1 |
| 89 | first-time | 989 |
| 90 | serine/arginine | 2 |
| 91 | 10-core | 16 |
| 92 | 20-core | 3 |
| 93 | 12-core | 43 |
| 94 | low-transverse | 2 |
| 95 | for-cause | 12 |
| 96 | 'date | 1 |
| 97 | no/late | 2 |
| 98 | deliberate | 255 |
| 99 | nonelective | 27 |
| 100 | pre-adoptive | 5 |
| 101 | non-ebf | 1 |
| 102 | suction-above-the-cuff | 2 |
| 103 | krf | 5 |
| 104 | all-consuming | 1 |
| 105 | 'morning | 8 |
| 106 | nrusing | 1 |
| 107 | non-reacting | 2 |
| 108 | drug-injecting | 1 |
| 109 | symptom-limiting | 1 |
| 110 | cg-rich | 1 |
| 111 | loughborough | 14 |
| 112 | second-look | 169 |
| 113 | biological-medical | 1 |
| 114 | mechanochemical | 13 |
| 115 | suprapreputial | 1 |
| 116 | nonoptimal | 17 |
| 117 | high-vaginal | 1 |
| 118 | transhumeral | 5 |
| 119 | groups.general | 1 |
| 120 | terminolateral | 3 |
| 121 | axillofemoral | 1 |
| 122 | angry-neutral | 1 |
| 123 | transmeatal | 2 |
| 124 | vaginal/rectal | 1 |
| 125 | nonrectal | 1 |
| 126 | intra-placental | 5 |
| 127 | left-prefrontal | 1 |
| 128 | free/total | 22 |
| 129 | btk/distal | 2 |
| 130 | fixed-interval | 11 |
| 131 | target-vessel | 87 |
| 132 | non-target-vessel | 2 |
| 133 | target\vessel | 1 |
| 134 | aminosilanetrithiol | 1 |
| 135 | 193-nm | 2 |
| 136 | 635-nm | 1 |
| 137 | 308-nm | 28 |
| 138 | 904nm | 2 |
| 139 | 'post-partum | 1 |
| 140 | clean | 1,006 |
| 141 | symptom-driven | 17 |
| 142 | parainflammation-driven | 1 |
| 143 | pharmacology-driven | 2 |
| 144 | pulmonary-vein | 11 |
| 145 | yomann | 1 |
| 146 | target-lesion | 56 |
| 147 | pre-termination | 2 |
| 148 | sugammadex/placebo | 1 |
| 149 | glu-pro | 1 |
| 150 | face-to | 8 |
| 151 | yo-yo | 50 |
| 152 | yoyo | 5 |
| 153 | short-scar | 2 |
| 154 | roentgenendovascular | 1 |
| 155 | trimodular | 2 |
| 156 | first-instar | 2 |
| 157 | ringleader | 5 |
| 158 | cystoscopy/bladder | 1 |
| 159 | pediveliger | 1 |
| 160 | geiger-muller | 1 |
| 161 | father-daughter | 4 |
| 162 | jehovah’s | 1 |
| 163 | repeat | 3,395 |
| 164 | 'repeat | 3 |
| 165 | hivnet | 7 |
| 166 | middle-of-the-night | 13 |
| 167 | full-night | 16 |
| 168 | half-unit | 1 |
| 169 | four-quadrant | 11 |
| 170 | hypertonicity-resistant | 1 |
| 171 | 3/7-dependent | 1 |
| 172 | semi-urgent | 13 |
| 173 | half-increment | 2 |
| 174 | 1-segment | 4 |
| 175 | less-frequent | 9 |
| 176 | closed-port | 1 |
| 177 | late-1st | 3 |
| 178 | no-cost | 14 |
| 179 | bypass-first | 1 |
| 180 | terawatt | 1 |
| 181 | 30-w | 1 |
| 182 | 2.5w | 1 |
| 183 | rapid-flow | 2 |
| 184 | 23-day | 3 |
| 185 | 256-day | 2 |
| 186 | same-day | 169 |
| 187 | 15-consecutive-day | 1 |
| 188 | bioguided-assay | 1 |
| 189 | over-daily | 1 |
| 190 | esthetic-only | 1 |
| 191 | bi-hourly | 3 |
| 192 | sole-therapy | 1 |
| 193 | non-culprit-artery | 1 |
| 194 | non-predatory | 2 |
| 195 | non-mandatory | 1 |
| 196 | high-medical-lethality | 1 |
| 197 | low-medical-lethality | 1 |
| 198 | celebrity | 16 |
| 199 | sucrose-density | 1 |
| 200 | reduced-activity | 2 |
| 201 | dirty | 57 |
| 202 | output.• | 1 |
| 203 | 02º | 1 |